HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- ((4- (6- methylpyridin- 2- yl)- 5- (quinolin- 6- yl)- 1H- imidazol- 2- yl)methyl)benzamide

a selective activin receptor-like kinase-5 inhibitor

Also Known As:

IN-1233

Networked: 4 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Kim, Dae-Kee: 4 articles (09/2011 - 02/2009)
2.	Kim, Jin Hyoung: 2 articles (09/2011 - 04/2010)
3.	Park, Hyung Gyu: 2 articles (09/2011 - 04/2010)
4.	Song, Ho-Young: 2 articles (09/2011 - 04/2010)
5.	Yoon, Hyun-Jung: 2 articles (09/2011 - 04/2010)
6.	Hong, Kang-Sun: 1 article (09/2011)
7.	Kim, Yeon Joo: 1 article (09/2011)
8.	Akhter, Hasina: 1 article (07/2011)
9.	Ballinger, Carol: 1 article (07/2011)
10.	Fanucchi, Michelle: 1 article (07/2011)

Related Diseases

1.	Hyperplasia 09/01/2011 - "IN-1233 was shown in this study to be effective for the prevention of neointimal hyperplasia after bare metallic stent placement in a rat CIA model." 09/01/2011 - "Role of IN-1233 in the prevention of neointimal hyperplasia after stent placement in a rat artery model." 09/01/2011 - "To evaluate the efficacy of an activin receptor-like kinase (ALK) 5 inhibitor, IN-1233, for the prevention of neointimal hyperplasia after bare stent placement in a rat common iliac artery (CIA) model. " 04/01/2010 - "To evaluate the efficacy of an activin receptor-like kinase-5 inhibitor, IN-1233, for the prevention of tissue hyperplasia after bare stent placement in a rat urethral model. "
2.	Vascular Remodeling 02/03/2009 - "Inhibition of activin receptor-like kinase-5 signaling in vivo with the selective small-molecule inhibitor IN-1233 prevented PAH, right ventricular hypertrophy, and vascular remodeling after monocrotaline injection and inhibited the progression of established PAH in this model. "
3.	Right Ventricular Hypertrophy 02/03/2009 - "Inhibition of activin receptor-like kinase-5 signaling in vivo with the selective small-molecule inhibitor IN-1233 prevented PAH, right ventricular hypertrophy, and vascular remodeling after monocrotaline injection and inhibited the progression of established PAH in this model. "
4.	Pulmonary Fibrosis (Fibrosing Alveolitis) 07/01/2011 - "To investigate the molecular mechanism underlying O₃-induced pulmonary fibrosis, 6- to 8-week-old C57BL/6 male mice were exposed to a cyclic O₃ exposure protocol consisting of 2 days of filtered air and 5 days of O₃ exposure (0.5 ppm, 8 h/day) for 5 and 10 cycles with or without intraperitoneal injection of IN-1233, a specific inhibitor of the type 1 receptor of transforming growth factor beta (TGF-β), the most potent profibrogenic cytokine. "

Related Drugs and Biologics

1.	Activin Receptors (Activin Receptor)
2.	Monocrotaline
3.	Transforming Growth Factor beta (TGF-beta)
4.	Cytokines

Related Therapies and Procedures

1.	Stents
2.	Intraperitoneal Injections